March 1, 2021REGENXBIO Reports Fourth Quarter and Full-Year 2020 Financial Results and Operational Highlights
February 22, 2021REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2020 Financial Results and Recent Operational Highlights
February 8, 2021RGX-121 Gene Therapy for Severe Mucopolysaccharidosis Type II (MPS II): Interim Results of an Ongoing First in Human TrialMarie-Laure Névoret, MD – Senior Clinical Development Lead, REGENXBIO
October 11, 2019Key Takeaways From The RGX-314 Phase I/IIa Clinical Trial For Wet AMD (Cohorts 1-5)Jeffrey Heier, MD – Ophthalmic Consultants of Boston
October 26, 2018Six Month Results of the Phase I Study to Evaluate Safety & Tolerability of RGX-314 Gene Therapy in nAMD SubjectsJeffrey Heier, MD – Ophthalmic Consultants of Boston
